Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis
NCT ID: NCT03498534
Last Updated: 2018-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2012-09-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Elispot will be used to measure TB development and the time for the bacteriological negativization and biochemical parameters as well as tuberculin skin test (TST), quantiferon, in contacts. (160 patients 600 contacts followed(continued) for 12 months). additional there will be evaluated the socioeconomic impact of both diseases and his(her) control. 1er year: transverse study and recruitment years 2 and 3 participants' follow-ups in clinical tests(essays).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus
NCT04600167
Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)
NCT03278483
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
NCT04830462
Treatment of Latent Tuberculosis Infection With Isoniazid
NCT00293228
Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis
NCT06054334
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with a -TST
In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months
Isoniazid 300Mg Tab
-TST tests will receive isoniazid 300Mg Tab for 6 months
Patients with a +TST
In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
Isoniazid 300 MG
\+ TST test will receive isoniazid 300MG Tab for 6 months
HIV positive patients
The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
Isoniazid 300 MG
HIV positive patient will receive isoniazid 300MGTab for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Isoniazid 300Mg Tab
-TST tests will receive isoniazid 300Mg Tab for 6 months
Isoniazid 300 MG
\+ TST test will receive isoniazid 300MG Tab for 6 months
Isoniazid 300 MG
HIV positive patient will receive isoniazid 300MGTab for 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Salud Publica, Mexico
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ma. de Lourdes Garcia Garcia
Director of the Center of Research in Infectious Diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Garcia-Garcia Lourdes, Doctor
Role: PRINCIPAL_INVESTIGATOR
National Institute of public Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CI-543
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.